Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Cash flows from operating activities:
Net (loss) income	$ (674,780)	$ 73,133	$ 158,153
Adjustments to reconcile net (loss) income to net cash provided by operating activities:
Depreciation and amortization, including patient equipment depreciation	382,783	351,178	258,053
Goodwill impairment	830,787	0	0
Equity-based compensation	22,468	22,397	25,323
Change in fair value of warrant liability	(34,482)	(17,158)	(53,181)
Change in fair value of contingent consideration common shares liability	0	0	(29,389)
Reduction in the carrying amount of operating lease right-of-use assets	31,873	32,264	28,624
Reduction in the carrying amount of finance lease right-of-use assets	5,938	0	0
Deferred income tax (benefit) expense	(62,595)	18,036	22,380
Change in fair value of interest rate swaps, net of reclassification adjustment	(1,801)	(2,936)	(2,927)
Amortization of deferred financing costs	5,234	5,234	5,378
Write-off of deferred financing costs	0	0	4,054
Loss on extinguishment of debt from prepayment penalty	0	0	16,135
Other	350	(285)	(3,615)
Changes in operating assets and liabilities, net of effects from acquisitions:
Accounts receivable	(28,862)	(209)	(29,694)
Inventory	15,531	(6,300)	(14,920)
Prepaid and other assets	(20,305)	(13,143)	2,731
Operating lease obligations	(32,428)	(31,213)	(28,043)
Operating liabilities	40,955	(57,131)	(83,383)
Net cash provided by operating activities	480,666	373,867	275,679
Cash flows from investing activities:
Purchases of equipment and other fixed assets	(337,463)	(391,423)	(203,308)
Payments for business acquisitions, net of cash acquired	(19,687)	(19,017)	(1,620,320)
Payments for cost method investments	(128)	(731)	(1,125)
Net cash used in investing activities	(357,278)	(411,171)	(1,824,753)
Cash flows from financing activities:
Proceeds from borrowings on long-term debt and lines of credit	50,000	0	1,165,000
Repayments on long-term debt and lines of credit	(95,000)	(20,000)	(827,271)
Repayments of finance lease obligations	(6,769)	(16,176)	(42,164)
Payments for shares purchased under share repurchase program	(29,275)	(13,992)	0
Payments for tax withholdings from restricted stock vestings and stock option exercises	(5,843)	(3,516)	(3,557)
Payments of contingent consideration and deferred purchase price from acquisitions	(2,535)	(14,493)	(25,233)
Payments relating to the Tax Receivable Agreement	(3,224)	0	0
Distributions to noncontrolling interests	(2,500)	(2,000)	(1,070)
Proceeds from the exercise of stock options	587	2,510	12,320
Proceeds received in connection with employee stock purchase plan	2,031	1,616	1,016
Proceeds from the issuance of senior unsecured notes	0	0	1,100,000
Proceeds from the issuance of Class A Common Stock	0	0	278,850
Payments for equity issuance costs	0	0	(13,832)
Payments of deferred financing costs	0	0	(29,185)
Payments for debt prepayment penalties	0	0	(16,135)
Net cash (used in) provided by financing activities	(92,528)	(66,051)	1,598,739
Net increase (decrease) in cash	30,860	(103,355)	49,665
Cash at beginning of period	46,272	149,627	99,962
Cash at end of period	77,132	46,272	149,627
Supplemental disclosures:
Cash paid for interest	126,228	108,885	73,630
Cash paid for income taxes	14,756	14,949	14,792
Noncash investing and financing activities:
Equipment acquired under finance lease obligations	0	1,335	22,959
Unpaid equipment and other fixed asset purchases at end of period	35,867	24,221	13,936
Assets subject to operating lease obligations	22,000	22,543	12,777
Operating lease obligations	(22,000)	(22,543)	(12,777)
Write-off of assets subject to operating lease obligations	(14,675)	(8,532)	0
Write-off of operating lease obligations	14,675	8,532	0
Assets subject to finance lease obligations	32,101	0	0
Finance lease obligations	(32,101)	0	0
Equity consideration issued in connection with acquisitions	0	0	1,261,200
Contingent purchase price in connection with acquisitions	0	0	7,800
Deferred purchase price in connection with acquisitions	$ 137	$ 457	$ 4,478